How Marco Pharma International Preserves German Homeopathic Traditions in America 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
BEVERLY, Mass. and TORONTO, April 18, 2018 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it will release its financial results for the three months and year ended December 31, 2017 before market open on Wednesday, April 25, 2018. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.com and on www.sedar.com.
The Company will follow with a conference call on the same day, at 11:00 a.m. EDT to review highlights of results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 3284638. A recording of the call will be available on Hamilton Thorne’s website shortly after the call.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
David Wolf, President & CEO Michael Bruns, CFO
Hamilton Thorne Ltd. Hamilton Thorne Ltd.
978-921-2050 978-921-2050
[email protected] [email protected]
